COSTEM 2019 | Varicella zoster virus vaccine for haematological malignancies

Per Ljungman

Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, discusses the use of an inactivated Varicella-zoster virus vaccine in patients with hematological malignancies for the prevention of shingles and herpes zoster in the post-transplant setting, specifically in the elderly. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video